Background In the last decade, the use of imatinib has brought a paradigm shift in the
management of chronic myeloid leukemia (CML). In India, imatinib has been available for …

This research purposed to formulate an optimized imatinib mesylate (IM)–loaded niosomes
to improve its chemotherapeutic efficacy. The influence of 3 formulation factors on niosomal …

This study was premeditated to elaborate an optimized imatinib mesylate (IM)–loaded
proniosomal–derived nanovesicles to investigate its influence on IM effectiveness, cellular …

查阅国内外相关文献, 根据不同作用靶点及相关癌症将已经成功上市和处于研发阶段的酪氨酸
激酶抑制剂进行分类整理与总结, 综述小分子酪氨酸激酶抑制剂的研究进展 …

Introduction: BCR-ABL fusion gene, the oncogenic driver of CML, results from a
translocation between short arms of chromosome 9 and 22. Monitoring of CML patients …

Despite the efficacy of imatinib mesylate (IM) in treating chronic myeloid leukemia (CML),
there is a high degree of resistance. Alpha-1-acid glycoprotein may reduce drug efficacy …

Background Tyrosine kinase inhibitors like imatinib have become the cornerstone of therapy
in chronic phase-chronic myeloid leukemia (CML-CP). However, the role of hydroxyurea …

Background: There is limited information on clinical characteristics, diagnosis and response
to therapy of patients with chronic myeloid leukaemia (CML) in Tanzania. This hospital …

The survival of patients with chronic myeloid leukemia (CML) has come close to healthy
normal individuals with the advent of tyrosine kinase inhibitor (TKI), imatinib in the start of the …

Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor, has been well established
as the standard of care for chronic myeloid leukaemia patients. In this study, we compared …